The inpatient burden of psoriasis in the United States.

[1]  J. Silverberg,et al.  Costs of Care for Hospitalization for Pemphigus in the United States. , 2016, JAMA dermatology.

[2]  D. Gladman,et al.  The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts , 2016, The Journal of Rheumatology.

[3]  T. Tung,et al.  Risk of Incident Chronic Kidney Disease and End-Stage Renal Disease in Patients with Psoriasis: a Nationwide Population-Based Cohort Study. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  G. Kerr,et al.  Psoriasis and psoriatic arthritis in African-American patients—the need to measure disease burden , 2015, Clinical Rheumatology.

[5]  M. Lebwohl,et al.  Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, JAMA dermatology.

[6]  A. Armstrong,et al.  Economic Burden of Psoriasis in the United States: A Systematic Review. , 2015, JAMA dermatology.

[7]  J. Silverberg.  Racial and Ethnic Disparities in Atopic Dermatitis , 2015, Current Dermatology Reports.

[8]  Herng‐Ching Lin,et al.  Psoriasis and the Risk of Pneumonia: A Population-Based Study , 2014, PloS one.

[9]  A. Wysong,et al.  Low rate of dermatology outpatient visits in Asian-Americans: an initial survey study for associated patient-related factors , 2014, BMC Dermatology.

[10]  A. Armstrong,et al.  Psoriasis prevalence among adults in the United States. , 2014, Journal of the American Academy of Dermatology.

[11]  E. Coto,et al.  Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta‐analysis , 2013, The British journal of dermatology.

[12]  L. Herrinton,et al.  Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009 , 2013, Pharmacoepidemiology and drug safety.

[13]  E. Armbrecht,et al.  Pediatric access to dermatologists: Medicaid versus private insurance. , 2013, Journal of the American Academy of Dermatology.

[14]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[15]  D. Symmons,et al.  Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review , 2012, Annals of the rheumatic diseases.

[16]  S. Feldman,et al.  Cause‐specific mortality in patients with severe psoriasis , 2010, The British journal of dermatology.

[17]  A. Troxel,et al.  Cause‐specific mortality in patients with severe psoriasis: a population‐based cohort study in the U.K. , 2010, The British journal of dermatology.

[18]  J. Gelfand,et al.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.

[19]  Cynthia S Crowson,et al.  Potential misclassification of patients with psoriasis in electronic databases. , 2008, Journal of the American Academy of Dermatology.

[20]  D. Mcgibbon,et al.  Inpatient management of psoriasis: a multicentre service review to establish national admission standards , 2007, The British journal of dermatology.

[21]  Andrea B Troxel,et al.  The risk of mortality in patients with psoriasis: results from a population-based study. , 2007, Archives of dermatology.

[22]  J. Resneck,et al.  Few Medicaid and uninsured patients are accessing dermatologists. , 2006, Journal of the American Academy of Dermatology.

[23]  F. Granath,et al.  Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.

[24]  C. Elmets,et al.  Dermatologic health disparities. , 2012, Dermatologic clinics.